Skip to main content

Editorial Board profiles


David Gorelick

Back to top

David Gorelick

David A. Gorelick, MD, PhD, DLFAPA, is Professor of Psychiatry (part-time) at the University of Maryland School of Medicine, having retired in October 2013 from the Intramural Research Program of the National Institute on Drug Abuse (NIDA), US National Institutes of Health (NIH) in Baltimore, Maryland.  

Dr Gorelick received his MD and PhD (pharmacology) degrees from the Albert Einstein College of Medicine of Yeshiva University, Bronx, New York in 1976, and did his medical internship and psychiatric residency at the University of California, Los Angeles. After completing training in 1980, he joined the faculty of the UCLA Department of Psychiatry and the medical staff of the West Los Angeles Veterans Affairs Medical Center, where he directed inpatient and outpatient substance abuse treatment programs. Dr Gorelick joined NIDA in 1989 as a tenured physician-scientist.  

His research interests are the clinical pharmacology of substance use, substance withdrawal, and biological treatments of substance use disorders, including medication, drug-metabolizing enzymes, and transcranial magnetic stimulation (TMS), resulting in more than 200 peer-reviewed scientific articles. Dr Gorelick has authored or co-authored more than 50 book chapters and spoken at major national and international medical and scientific conferences. His recent work focuses on cannabis (including its potential therapeutic uses), cocaine, and individuals with co-morbid psychiatric disorders.  

Dr Gorelick is board certified in psychiatry and addiction medicine, and a distinguished life fellow of the American Psychiatric Association. Dr Gorelick is also interested in the ethics of clinical research, serving for 10 years as chair of the NIDA Institutional Review Board and as a member of the NIH Human Subjects Research Advisory Committee and the NIH Committee on Scientific Conduct and Ethics.

Section Editors

Sharon Anavi-Goffer

Back to top

Sharon Anavi-GofferSharon Anavi-Goffer is Honorary Senior Lecturer at the School of Medicine, Medical Sciences and Nutrition, Institute of Medical Sciences, University of Aberdeen, Scotland.  

Dr Anavi-Goffer's research is focused on the pharmacology of cannabinoids and cellular distribution of the cannabinoid receptors. Working with GW Pharmaceuticals she played a major role in discovery of the structure-activity-relationship of phytocannabinoids at the GPR55, promoting the development of CBDV to treat neuroblastoma. 

Dr Anavi-Goffer’s current research is directed at the role of the cannabinoid system in mental diseases. Her research has been funded by the Tourette Association of America (TAA) and the National Institute for Psychobiology in Israel, focusing on the development of new drugs to treat Tourette syndrome and schizophrenia. Dr Anavi-Goffer is member of the Advisory Committee of the Tourette Syndrome Association of Israel and a member of the TAA International Consortium for Medical Cannabis and Related Drugs for Tic Disorders.

Dr Anavi-Goffer is the Journal of Cannabis Research Section Editor for the Endocannabinoid system.

Nirit Bernstein

Back to top

New Content Item

Nirit Bernstein is a senior research scientist at Agricultural Research Organization, Volcani Center, at the Institute of Soil, Water, and Environmental Sciences, and Head of the Department of Soil Physics and Irrigation, Israel. 

A Plant Physiologist by training, Dr Bernstein's research focuses on control mechanisms for production of plant derived pharmaceuticals in medicinal plants by manipulation of environmental conditions and agronomic practices, optimization of agrotechniques for environmentally stressed plants, mineral nutrition of plants, and plant stress physiology. 

Dr Bernstein is also the first scientist in Israel to study cannabis – whole plant, and her current work involves physiology, biochemistry, optimization of cultivation practices, and improvement of genetic material of cannabis.

Dr Bernstein is the Journal of Cannabis Research Section Editor for Agriculture and plant biology.

Claudio D'Addario

Back to top

Claudio D'AddarioClaudio D’Addario is Professor of Molecular Biology at the Faculty of Bioscience, University of Teramo (Italy) and affiliated researcher at the Karolinska Institute (Sweden). He was trained in pharmacology and clinical neuroscience. 

Dr D'Addario's research interest is the study of the behavioral and molecular events occurring in the central nervous system in different psychiatric conditions, focusing in particular on the role of the epigenetic mechanisms in the transcriptional regulation of relevant components of endogenous systems, such as the opioid and the endocannabinoid systems.

Dr D'Addario is the Journal of Cannabis Research Section Editor for Cannabis and cannabinoid biochemistry and genetics.

Brain Fairman

Back to top

Renee JohnsonBrian Fairman is an epidemiologist whose primary interest is in understanding and addressing drug use, addiction, and related health consequences in the population. One of the areas he studies is how social contexts, such as neighborhoods, policies, and peers/families, influence drug-using behaviors over time. He also investigates how people use drugs from how they combine them to new methods of consumption. 

Dr Fairman is the Journal of Cannabis Research Section Editor for Epidemiology and public health.

Celia Morgan

Back to top

Celia MorganCelia Morgan is Professor of Psychopharmacology at University of Exeter, UK. 

Dr Morgan is interested in the effects of cannabis on the brain and behavior. Her research has concentrated on examining both the positive and negative effects of cannabinoids on cognition and addiction, through behavioural and neuroimaging studies. 

Her work also has focused on what makes individuals vulnerable to the harmful effects of certain substances, like cannabis. More recently, she has begun to investigate the potentially therapeutic sides of cannabinoids in clinical trials.

Dr Morgan is the Journal of Cannabis Research Section Editor for Cannabis and cannabinoid clinical pharmacology.

Charles Schindler

Back to top

Charles Schindler

Charles W. Schindler received his Ph.D. in Experimental Psychology from American University in 1980. After a post-doctoral fellowship at the University of Iowa, he joined the NIDA IRP in 1985 as a Staff Fellow in the laboratory of Dr. Steven R. Goldberg. The focus of his early research was on determining the cardiovascular effects of psychomotor stimulants, in particular cocaine, and how those effects might be altered following drug treatment. 

Throughout his tenure with Dr. Goldberg, he also maintained an interest in the behavioral effects of drugs of abuse, and in particular drug self-administration. He joined the Designer Drug Unit (DDRU) in 2016 as a Staff Scientist. His research is currently focused on the behavioral and physiological effects of designer drugs, in particular the synthetic cathinones.

Dr Schindler is the Journal of Cannabis Research Section Editor for Cannabis and cannabinoids preclinical pharmacology.